EUROPEAN COMMISSION

DIRECTORATE-GENERAL FOR RESEARCH & INNOVATION

SP4-Capacities

Coordination and support action

Support actions

FP7-REGPOT-2012-2013-1

Grant Agreement Number 316265

BIOCAPS

BIOMEDICAL CAPACITIES SUPPORT PROGRAM

FP7-REGPOT-2012-CT2012-316265

Centro Solicitante: FUNDACION BIOMEDICA DEL COMPLEJO HOSPITALARIO DE VIGO

Centro Realizador: COMPLEJO HOSPITALARIO DE VIGO

Título: Radioterapia adaptativa y predicción de la respuesta tumoral basadas en estudios funcionales de RM y PET/CT en cáncer de cabeza y cuello

RESOLUCIÓN PROVISIONAL DE CONCESIÓN

Estado de Resolución Provisional de Concesión : NO CONCEDIDO

CAUSA PROVISIONAL DE DENEGACIÓN

El estudio es ambicioso pero muy confuso desde el punto de vista conceptual y procedimental.
Se mezcla perfusión, densidad celular, hipoxia y metabolismo tumoral como si todos estuvieran necesariamente ligados y no tuvieran carácter independiente. La densidad celular no tiene por qué estar asociada a viabilidad tumoral y la perfusión no tiene por qué estar ligada a la hipoxia tumoral. La viabilidad tumoral y la hipoxia son parámetros decisivos en radioterapia y solo pueden ser determinados por medio de radiotrazadores específicos PET (FDG; FMISO).
En el proyecto no se define el papel fundamental de esta técnica lo cual es un error de planteamiento. Lamentablemente el desarrollo de las correlaciones biológicas de respuesta con el tratamiento es muy poco profundo y creemos que sería de gran valor un mayor detalle en estos análisis.
Al final, las pruebas de imagen tanto por MRI-perfussion como por PET-CT sugieren marcadores subrogados. En este sentido, un marcador subrogado no sólo debe tener un gran modelo predictivo detrás (el generado por el subproyecto 2) sino que debe tener sentido biológico. Para ello es necesaria una correlación exquisita con el evento biológico que se desea medir (proliferación celular en el tumor). Se sugiere que los autores planteen con mayor profundidad el análisis del evento biológico in vivo pues todas las conclusiones posteriores dependerán de éste.

RESOLUCIÓN DEFINITIVA DE CONCESIÓN

Estado de Resolución Definitiva de Concesión : CONCEDIDO

PRESUPUESTO CONCEDIDO DEFINITIVO

	1ª ANUALIDAD	2ª ANUALIDAD	3ª ANUALIDAD	TOTAL
BIENES/SRV	20.000,00	20.000,00	20.000,00	**60.000,00**
PERSONAL	12.500,00	0,00	0,00	**12.500,00**
VIAJES	750,00	250,00	250,00	**1.250,00**
SUBTOTALES	**33.250,00**	**20.250,00**	**20.250,00**	**73.750,00**
Costes ind. 21,00 %	6.982,50	4.252,50	4.252,50	15.487,50
TOTALES	**40.232,50**	**24.502,50**	**24.502,50**	**89.237,50**

PERSONAL CONCEDIDO DEFINITIVO CON CARGO AL PROYECTO

Personal con Cargo	Concedido Definitivo
Titulado superior	0
Titulado medio	0
Técnico FP	0

EQUIPO DE INVESTIGACIÓN

Nombre	Apellido 1	Apellido 2	Tipo	Ded.
ANTONIO	LOPEZ	MEDINA	Colaborador	UNICA
MERCEDES	ARIAS	GONZALEZ	Colaborador	COMPARTIDA
ANA MARIA	LOPEZ	LOPEZ	Colaborador	UNICA
JOSE MANUEL	NOGUEIRAS	ALONSO	Colaborador	COMPARTIDA
VICTOR MANUEL	MUÑOZ	GARZON	IP	UNICA
MARIA BEGOÑA	IGLESIAS	RODRIGUEZ	Colaborador	COMPARTIDA
EDUARDO	MEILAN	BERMEJO	Colaborador	COMPARTIDA
FRANCISCO JAVIER	SALVADOR	GOMEZ	Colaborador	UNICA
IÑIGO	NIETO	REQUEIRA	Colaborador	COMPARTIDA
JULIO SANTIAGO	VAZQUEZ	RODRIGUEZ	Colaborador	COMPARTIDA
LORENA	PEREIRA	FERRADAS	Colaborador	COMPARTIDA
YOLANDA	LORENZO	MAHIA	Colaborador	COMPARTIDA
ALFONSO	IGLESIAS	CASTAÑON	Colaborador	COMPARTIDA
VIRGINIA	OCHAGAVIA	GALILEA	Colaborador	COMPARTIDA

ANEXO I- RESOLUCIÓN DEL DIRECTOR DEL INSTITUTO DE SALUD CARLOS III POR LA QUE SE CONCEDEN SUBVENCIONES PARA PROYECTOS DE INVESTIGACIÓN EN SALUD (MODALIDAD PROYECTOS DE DESARROLLO TECNOLÓGICO EN SALUD) DE LA CONVOCATORIA 2014 DE LA ACCIÓN ESTRATÉGICA EN SALUD 2013-2016

AUTONOMÍA	CENTRO	CIF	EXPEDIENTE	TITULO	CONCEDIDO		
					Total	1ª anualidad	2ª anualidad
ANDALUCIA							
	EMPRESA PUBLICA DE EMERGENCIAS SANITARIAS	Q2900463G	DTS14/00242	Plataforma de Abordaje Integral del ictus en Fase Aguda (AID-ictus)	56.100,00 €	38.500,00 €	17.600,00 €
	FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD EN SEVILLA	G41918830	DTS14/00143	Plataforma de Abordaje Integral del ictus en Fase Aguda (AID-ictus)	144.100,00 €	93.500,00 €	50.600,00 €

AUTONOMÍA	CENTRO	CIF	EXPEDIENTE	TITULO	CONCEDIDO		
					Total	1ª anualidad	2ª anualidad
CATALUÑA							
	FUNDACION INSTITUTO DE INV. DR. JOSEP TRUETA	G17432592	DTS14/00087	Dispositivo Point of Care de Diagnóstico del Ictus mediante Biomarcadores Plasmáticos: 2-Stroke-Chip	16.500,00 €	11.000,00 €	5.500,00 €
	FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON	G60594009	DTS14/00004	"Dispositivo Point of Care de Diagnóstico del Ictus mediante Biomarcadores Plasmáticos: 2-Stroke-Chip".	155.650,00 €	110.550,00 €	45.100,00 €
	FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL	G60805462	DTS14/00099	Dispositivo Point of Care de Diagnóstico del Ictus mediante Biomarcadores Plasmáticos: 2-Stroke-Chip	13.750,00 €	11.000,00 €	2.750,00 €
	FUNDACION PARC TAULI	G60331238	DTS14/00108	"Dispositivo Point of Care de Diagnóstico del Ictus mediante Biomarcadores Plasmáticos: 2-Stroke-Chip".	12.650,00 €	7.700,00 €	4.950,00 €

AUTONOMÍA	CENTRO	CIF	EXPEDIENTE	TITULO	CONCEDIDO		
					Total	1ª anualidad	2ª anualidad
COM. VALENCIANA							
	FUNDACION PARA EL FOMENTO DE LA INV. SANITARIA Y BIOMEDICA DE LA COMUNIDAD VALENCIANA (FISABIO)	G98073760	DTS14/00185	Gestión de crónicos apoyada en tecnologías innovadoras en la Comunidad Valenciana. Evaluación de su efectividad y eficiencia en la práctica habitual.	19.250,00 €	2.750,00 €	16.500,00 €
	FUNDACION PARA LA INVESTIGACION DEL HOSPITAL LA FE	G97067557	DTS14/00123	DESARROLLO DE UNA ESTRATEGIA INNOVADORA PARA LA GESTION DE PACIENTES CRONICOS APOYADA EN EL USO DE TECNOLOGIAS “INTELIGENTES” DE LA INFORMACION PARA SU TRANFERENCIA AL SECTOR SANITARIO.	150.150,00 €	99.550,00 €	50.600,00 €

AUTONOMÍA	CENTRO	CIF	EXPEDIENTE	TITULO	CONCEDIDO		
					Total	1ª anualidad	2ª anualidad
GALICIA							
	FUNDACION BIOMEDICA GALICIA SUR	G36911972	DTS14/00188	Web-based tools for Neuroimaging and Radiotherapy Functional Analysis & Quantification - ARTFIBio	52.250,00 €	39.050,00 €	13.200,00 €
	FUNDACION RAMON DOMINGUEZ	G15796683	DTS14/00158	Web-based tools for Neuroimaging and Radiotherapy Functional Analysis & Quantification (subproyecto IQ-BRAIN)	62.150,00 €	39.050,00 €	23.100,00 €

AUTONOMÍA	CENTRO	CIF	EXPEDIENTE	TITULO	CONCEDIDO		
					Total	1ª anualidad	2ª anualidad
MADRID							
	FUNDACION INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON	G83195305	DTS14/00192	Navegación y guiado de aceleradores móviles para tratamientos de radioterapia intraoperatoria	89.650,00 €	66.550,00 €	23.100,00 €
	INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ	G85874949	DTS14/00229	Navegación y guiado de aceleradores móviles para tratamientos de radioterapia intraoperatoria	56.650,00 €	52.827,50 €	3.822,50 €

AUTONOMÍA	CENTRO	CIF	EXPEDIENTE	TITULO	CONCEDIDO		
					Total	1ª anualidad	2ª anualidad
PAIS VASCO							
	ASOCIACION INSTITUTO BIODONOSTIA	G75020313	DTS14/00109	Blood-based cancer detection: Development of an economical, sensitive and rapid sensor to detect cancer-associated DNA	122.100,00 €	82.500,00 €	39.600,00 €
	FUNDACION ONKOLOGIKOA	G75023184	DTS14/00116	Blood-based cancer detection: Development of an economical, sensitive and rapid sensor to detect cancer-associated DNA	48.950,00 €	45.375,00 €	3.575,00 €

Project Information

3P30CA008748-50S6

Back to Query Form | Back to Search Results | Print Version

Project 4 of 22

DESCRIPTION DETAILS RESULTS HISTORY SUBPROJECTS CLINICAL STUDIES SIMILAR PROJECTS NEARBY PROJECTS BETA LINKS NEWS AND MORE

Project Number: 3P30CA008748-50S6
Title: CANCER CENTER SUPPORT GRANT

Contact PI / Project Leader: THOMPSON, CRAIG B
Awardee Organization: SLOAN-KETTERING INST CAN RESEARCH

Abstract Text:

SUPPORT FOR NATIONAL PRIMATE RESEARCH CENTER Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing NCI-designated Comprehensive Cancer Research Center dedicated to research and training, with the mission of changing and setting the standards of treatment, prevention and control of cancer through inpatient and outpatient care. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Molecular Structure); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Survivorship, Outcomes and Risk). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based Investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the 10 research programs depends on services provided by 34 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 21 of these core facilities. During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs in key research areas. Support is requested to provide developmental funding for the laboratories of new Investigators recruited in research areas aligned with the Center's strategic vision, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Public Health Relevance Statement:

RELEVANCE (See instructions): Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities.

Project Terms:

Ambulatory Care; Area; base; Basic Science; Cancer Biology; Cancer Center Support Grant; Cancer Control; Categories; cell behavior; Clinical; Clinical Research; Core Facility; design; Detection; Development; Diagnosis; Experimental Pathology; Funding; genome integrity; Image; Immunology; Inpatients; Institution; Instruction; Investigational Therapies; Laboratories; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mission; Molecular Structure; NCI Center for Cancer Research; Outcome; patient oriented research; patient population; Pilot Projects; Population Sciences; Prevention; Primates; programs; Radiation; Recruitment Activity; Regulation; Research; Research Activity; research facility; Research Personnel; Research Training; Risk; Science; Services; standard care; stem cell biology; survivorship; Training Programs; Transplantation; Vision; Work

Dave, Amita/Medical Physics

From: Schwartz, Beverly/Radiation Oncology
Sent: Monday, August 18, 2014 2:58 PM
To: Lee, Nancy/Radiation Oncology
Cc: Dave, Amita/Medical Physics; Riaz, Nadeem/Graduate Medical Education; Zhang, Zhigang/Epidemiology-Biostatistics; Young, Robert J./Radiology; Hatzoglou, Vaios/Radiology; Oh, Jung Hun/Medical Physics
Subject: IMRAS Grant Award

Importance: High

Dear Dr. Lee:

Congratulations!

The IMRAS Steering Committee is pleased to announce that you have been selected to receive an IMRAS grant for your proposal on "Personalizing radiotherapy: using weekly quantitative MRI metrics of cellularity and vascularity and genomic analysis to develop a framework for individualized dose prescriptions for head and neck cancers."

Thank you for your proposal, collaborative efforts and hard work. We look forward to seeing the accomplishments achieved as a result of your proposal.

Sincerely,

Beverly Schwartz
On behalf of Dr. Simon Powell

Dr. Amita Shukla-Dave Co-PI in the grant
Dr. Vaios Hatzoglou Co-Investigator in the grant

SEVENTH FRAMEWORK PROGRAMME

GRANT AGREEMENT No 316265

PROJECT TITLE BIOCAPS

Coordination and support action

Support actions

The **European Union** ("*the Union*"), represented by the **European Commission** (the "*Commission*"),

of the **one part,**

and UNIVERSIDAD DE VIGO, established in LG CAMPUS LAGOAS-MARCOSENDE, PONTEVEDRA, VIGO, 36310, Spain represented by María Asunción Longo González, Vice-Rector of Research and/or Manuel Castro Oliva, Chief of Research Service or their authorised representative, the *beneficiary* acting as "*coordinator*" of the *consortium* (the "*coordinator*"), ("*beneficiary no. 1*"),

of the **other part**

HAVE AGREED to the following terms and conditions including those in the following annexes, which form an integral part of this *grant agreement* (the "*grant agreement*").

Annex I - Description of Work
Annex II - General conditions
Annex III - Non applicable
Annex IV - Non applicable
Annex V - Non applicable
Annex VI - Form C - Financial statement per funding scheme
Annex VII - Form D - Terms of reference for the certificate on the financial statements and Form E - Terms of reference for the certificate on the methodology

Article 1 - Accession to the *grant agreement* of the other *beneficiaries*

1. The *coordinator* shall endeavour to ensure that each legal entity identified below accedes to this *grant agreement* as a *beneficiary*, assuming the rights and obligations established by the *grant agreement* with effect from the date on which the *grant agreement* enters into force, by signing Form A in three originals, countersigned by the *coordinator*.

All the *beneficiaries* together form the *consortium* (the "*consortium*").

2. The *coordinator* shall send to the *Commission* one duly completed and signed Form A per *beneficiary* at the latest 45 calendar days after the entry into force of the *grant agreement*. The two remaining signed originals shall be kept, one by the *coordinator* to be made available for consultation at the request of any *beneficiary*, and the other by the *beneficiary* concerned.

3. Should any legal entity identified above, fail or refuse to accede to the *grant agreement* within the deadline established in the previous paragraph, the *Commission* is no longer bound by its offer to the said legal entity(ies). The *consortium* may propose to the *Commission*, within the time-limit to be fixed by the latter, appropriate solutions to ensure the implementation of the *project*. The procedure established in Annex II for amendments to this *grant agreement* will apply.

Article 2 - Scope

The Union has decided to grant a financial contribution for the implementation of the *project* as specified in Annex I, called *BIOMEDICAL CAPACITIES SUPPORT PROGRAM (BIOCAPS)* (the "*project*") within the framework of the *SP4-Capacities* and under the conditions laid down in this *grant agreement*.

Article 3 - Duration and *start date* of the *project*

The duration of the *project* shall be 42 months from 1st February 2013 (hereinafter referred to as the "*start date*").

Article 4 - Reporting periods and language of reports

The *project* is divided into reporting periods of the following duration:

- P1: from month 1 to month 18
- P2: from month 19 to month 36
- P3: from month 37 to the last month of the *project*.

Any report and deliverable, when appropriate, required by this *grant agreement* shall be in *English*.

Article 5 - Maximum financial contribution of *the Union*

1. The maximum financial contribution of *the Union* to the *project* shall be EUR 4,610,710.00 (*four million six hundred and ten thousand seven hundred and ten EURO*). The actual financial contribution of *the Union* shall be calculated in accordance with the provisions of this *grant agreement*.

2. Details of the financial contribution of *the Union* are contained in Annex I to this *grant agreement* which includes:

- a table of the estimated breakdown of budget and financial contribution of *the Union* per activity to be carried out by each of the *beneficiaries* under the *project*. *Beneficiaries* are allowed to transfer budget between different activities and between themselves in so far as the work is carried out as foreseen in Annex I.

3. The bank account of the *coordinator* to which all payments of the financial contribution of *the Union* shall be made is:

Name of account holder: UNIVERSIDAD DE VIGO
Name of bank: La Caixa
Account reference: ES9521002177680200401690

Article 6 - Pre-financing

A *pre-financing* of EUR 3,688,568.00 (*three million six hundred and eighty eight thousand five hundred and sixty eight EURO*) shall be paid to the *coordinator* within 45 days following the date of entry into force of this *grant agreement*. The *coordinator* shall distribute the *pre-financing* only to the *beneficiaries* who have acceded to the *grant agreement* and after the minimum number of *beneficiaries* required by the *Rules for Participation* as detailed in the call for proposals to which the *project* is related, have acceded to the *grant agreement*.

Beneficiaries hereby agree that the amount of EUR *230,535.50* (*two hundred and thirty thousand five hundred and thirty five EURO and fifty cents*), corresponding to the *beneficiaries'* contribution to the Guarantee Fund referred to in Article II.20 and representing 5% of the maximum financial contribution of *the Union* referred to in Article 5.1, is transferred in their name by the *Commission* from the *pre-financing* into the Guarantee Fund. However, *beneficiaries* are deemed to have received the full *pre-financing* referred to in the first indent and will have to justify it in accordance with the *grant agreement*.

Article 7 - Special clauses

The following special clauses apply to this *grant agreement*:

Special clause 4

All references to the "*beneficiaries*" or to the "*consortium*" or to the "*coordinator*" in this *grant agreement* and in the Annexes thereto shall be interpreted as references to the "*beneficiary*".

Special clause 6

Notwithstanding the provisions of Article 6 the *pre-financing* shall be paid not earlier than 45 days before the *start date* of the *project*.

Special clause 10

1. The following third parties are linked to UNIVERSIDAD DE VIGO:

- SERVIZO GALEGO DE SAUDE

2. This *beneficiary* may charge costs incurred by the above mentioned third parties in carrying out the *project*, in accordance with the provisions of the *grant agreement*. These contributions shall not be considered as receipts of the *project*.

The third parties shall identify the costs to the *project* mutatis mutandis in accordance with the provisions of part B of Annex II of the *grant agreement*. Each third party shall charge its eligible costs in accordance with the principles established in Articles II.14 and II.15. The *beneficiary* shall provide to the *Commission*:

- an individual financial statement from each third party in the format specified in Form C. These costs shall not be included in the *beneficiary's* Form C.

- certificates on the financial statements and/or on the methodology from each third party in accordance with the relevant provisions of this *grant agreement*.

- a summary financial report consolidating the sum of the eligible costs borne by the third parties and the *beneficiary*, as stated in their individual financial statements, shall be appended to the *beneficiary's* Form C.

When submitting reports referred to in Article II.4, the *consortium* shall identify work performed and resources deployed by each third party linking it to the corresponding *beneficiary*.

3.The eligibility of the third parties' costs charged by the *beneficiary* is subject to controls and audits of the third parties, in accordance with Articles II.22 and 23.

4. The *beneficiary* shall retain sole responsibility towards *the Union* and the other *beneficiaries* for the third parties linked to it. The *beneficiary* shall ensure that the third parties abide by the provisions of the *grant agreement*.

Article 8 - Communication

1. Any communication or request concerning the *grant agreement* shall identify the *grant agreement* number, the nature and details of the request or communication and be submitted to the following addresses:

For the *Commission*: European Commission
Directorate-General for Research & Innovation
RTD/C.5 - Regional Dimension of Innovation
B-1049 Brussels, Belgium

For the *coordinator*: Mr. Anxo Moreira González
UNIVERSIDAD DE VIGO
Servicio de Apoyo a la investigacion, Edificio Gerencia
LG CAMPUS LAGOAS-MARCOSENDE
PONTEVEDRA, VIGO 36310
SPAIN

2. For information or documents to be transferred by electronic means, the following addresses shall be used:

For the *Commission*: RTD-REGIONS-REGPOT-GA@ec.europa.eu

For the *coordinator*: otri9@uvigo.es

3. In case of refusal of the notification or absence of the recipient, the *beneficiary* or the *consortium*, as the case may be, is deemed to have been notified on the date of the latest delivery, if notification to the *coordinator* has been sent to one of the addresses mentioned in paragraphs 1 and 2 and to their legal representative. Other *beneficiaries* are deemed to have been notified if notification has been sent to the address mentioned in Article 1.1.

4. Any communication or request relating to the processing of personal data (Article II.13) shall be submitted, using the address(es) for the *Commission* identified in paragraphs 1 and 2, to the Controller responsible for the processing: Head of Unit of RTD/C.5 - Regional Dimension of Innovation.

Article 9 - Applicable law and competent court

The financial contribution of *the Union* is a contribution from *the Union* research budget with the aim to implement the 7th Research Framework Programme (FP7) and it is incumbent on the Commission to execute FP7. Accordingly, this *grant agreement* shall be governed by the terms of this *grant agreement*, the European Community and European Union acts related to FP7, the Financial Regulation applicable to the general budget and its implementing rules and other European Community and European Union law and, on a subsidiary basis, by the law of Belgium.

Furthermore the *beneficiary* is aware and agrees that the Commission may take a decision to impose pecuniary obligations, which shall be enforceable in accordance with Article 299 of the Treaty on the Functioning of the European Union and Articles 164 and 192 of the Treaty establishing the *European Atomic Energy Community*.

Notwithstanding the *Commission's* right to directly adopt the recovery decisions referred to in the previous paragraph, the General Court, or on appeal, the Court of Justice of the European Union, shall have sole jurisdiction to hear any dispute between *the Union* and any *beneficiary* concerning the interpretation, application or validity of this *grant agreement* and the validity of the decision mentioned in the second paragraph.

Article 10 - Application of the *grant agreement* provisions

Any provision of this part of the *grant agreement*, shall take precedence over the provisions of any of the Annexes. The provisions of Annex III shall take precedence over the provisions of Annex II, and both shall take precedence over the provisions of Annex I.

The special clauses set out in Article 7 shall take precedence over any other provisions of this *grant agreement*.

Article 11 - Entry into force of the *grant agreement*

This *grant agreement* shall enter into force after its signature by the coordinator and the *Commission*, on the day of the last signature.

Done in two originals in English.

For the *coordinator* done at Pontevedra, Vigo

Universidad de Vigo
Name of the legal entity

Manuel Castro Oliva
Name of the legal representative

Stamp of the organisation (if applicable)

Chief of Research Service
Signature of legal representative

22/08/2012
Date

For the *Commission* done at Brussels

Clara de la Torre
Director
Research and Innovation
DG RESEARCH AND INNOVATION

Name of the legal representative

Signature of legal representative

Date